(NASDAQ: ARDX) Ardelyx's forecast annual revenue growth rate of 18.12% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 104.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.71%.
Ardelyx's revenue in 2025 is $398,234,000.On average, 13 Wall Street analysts forecast ARDX's revenue for 2025 to be $99,468,821,390, with the lowest ARDX revenue forecast at $94,738,111,652, and the highest ARDX revenue forecast at $103,093,998,036. On average, 13 Wall Street analysts forecast ARDX's revenue for 2026 to be $127,129,016,385, with the lowest ARDX revenue forecast at $101,687,176,804, and the highest ARDX revenue forecast at $143,848,078,381.
In 2027, ARDX is forecast to generate $160,589,008,065 in revenue, with the lowest revenue forecast at $144,287,861,875 and the highest revenue forecast at $194,658,865,252.